Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Recombinant IL-6R (Tocilizumab Biosimilar) antibody

The Humanized Monoclonal anti-IL-6R (Tocilizumab Biosimilar) antibody has been validated for ELISA and FACS. It is suitable to detect IL-6R (Tocilizumab Biosimilar) in samples from Human.
Catalog No. ABIN7093060

Quick Overview for Recombinant IL-6R (Tocilizumab Biosimilar) antibody (ABIN7093060)

Target

IL-6R (Tocilizumab Biosimilar)

Antibody Type

Recombinant Antibody

Reactivity

Human

Host

  • 2
  • 1
  • 1
  • 1
Humanized

Clonality

  • 3
  • 2
Monoclonal

Conjugate

  • 4
  • 1
This IL-6R (Tocilizumab Biosimilar) antibody is un-conjugated

Application

  • 4
  • 2
  • 1
ELISA, Flow Cytometry (FACS)

Grade

Research Grade
  • Purpose

    Anti-IL6R (tocilizumab biosimilar) mAb

    Characteristics

    MRA, atlizumab, rhPM-1

    Purification

    Purified from cell culture supernatant by affinity chromatography

    Isotype

    IgG1
  • Application Notes

    ELISA 1:5000-10000, Flow Cyt 1:100

    Comment

    Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.

    Restrictions

    For Research Use only
  • Format

    Lyophilized

    Reconstitution

    Reconstitute with deionized water

    Buffer

    Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose is added as protectants before lyophilization.

    Storage

    -20 °C,-80 °C

    Storage Comment

    Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.

    Expiry Date

    12 months
  • Target

    IL-6R (Tocilizumab Biosimilar)

    Alternative Name

    IL6R (Tocilizumab Biosimilar)

    Target Type

    Biosimilar

    Background

    Synonyms: CD126, gp80, IL-6R-1, IL-6RA, IL6Q, IL6RA, IL6RQ

    Gene ID

    3570

    UniProt

    P08887
You are here:
Chat with us!